Category: Danaher Corp.
The $2.14 billion acquisition of Nobel Biocare will turn Danaher into the largest dental implants provider in the world.
Here's a look at some of the top Wall Street stories for medical device companies this week: Covidien snaps up Reverse Medical; Standard & Poor's maintains credit watch on Medtronic over Covidien buy; Allergan can't delay shareholder vote on hostile Valeant bid; Medtronic drops $200M on Dutch DBS firm Sapiens; Nobel Biocare's Q2 profits double as it fields buyout interest
, Danaher Corp.
, Dentsply International Inc.
, Nobel Biocare Holdings AG
, Pershing Square Capital Management
, Reverse Medical Corp.
, Sapiens Brain Steering Stimulation GmbH
, Standard & Poor's
, Valeant Pharmaceuticals
, Allergan Inc.
Nobel Biocare doubles its 2nd-quarter profits as it reportedly fields interest – and at least 1 offer worth $2.3 billion – from potential acquirers.
Here's a look at some of the top regulatory stories for medical device companies this week: Johnson & Johnson eyes acquisitions in cardiovascular, elsewhere; Abbott CEO defends inversions amid corporate exodus furor; Medtronic fights tax dodging rhetoric in Covidien merger; Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Siemens sells clinical microbiology biz to Beckman Coulter
Beckman Coulter picks up Siemens Healthcare Diagnostics' clinical microbiology business in a closed-doors deal.
Danaher Corp. and private equity behemoth Blackstone are joining forces in the hunt for Johnson & Johnson's Ortho Clinical Diagnostics unit, anonymous sources tell Reuters.
Shares of Danaher Corp. rise after it beats Wall Street's earnings forecast and affirms its outlook for the rest of the year.
Danaher (NYSE:DHR) shares gained today after the conglomerate shattered Wall Street's 3rd-quarter earnings expectations and affirmed its outlook for the balance of 2013.